SCHEMBL1250322

SCHEMBL1250322

Cc1cc(C)c(O)c(C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
KDM4E B2RXH2 6/20 0.41
MAPT P10636 4/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 1/20 0.39
POLB P06746 3/20 0.38
CYP1A2 P05177 3/20 0.37
NQO2 P16083 1/20 0.35
NPC1 O15118 1/20 0.35
MITF O75030 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
AGTR1 P30556 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30837586 1.00 CA1 (0.43) CA1CA2KDM4EMAPTALDH1A1
Oxalic Acid SCHEMBL1252610 0.89 ALDH1A1 (0.46) CA1CA2KDM4EMAPTALDH1A1
Succinic Acid SCHEMBL1251838 0.84 KDM4E (0.46) KDM4EMAPTALDH1A1SMN1; SMN2MAPK1
Maleic Acid SCHEMBL1250309 0.84 ALDH1A1 (0.42) KDM4EMAPTALDH1A1LMNAGAA
Fumaric Acid SCHEMBL1250313 0.84 ALDH1A1 (0.42) KDM4EMAPTALDH1A1LMNAGAA
Cadaverine Tartrate SCHEMBL1251771 0.82 MAPK1 (0.41) KDM4EMAPTALDH1A1LMNAGAA
SCHEMBL8814883 0.79 SELL (0.43) CA1CA2KDM4EMAPTALDH1A1
SCHEMBL24529687 0.75 MAPT (0.46) MAPTALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL21851374 0.75 VRK1 (0.41) KDM4EMAPTLMNAGAAPOLB
SCHEMBL25111458 0.75 CA1 (0.40) CA1CA2KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117757523-A Multi-component scale inhibitor and method for preventing scale in petrochemical production 江苏太湖新材料技术研发有限公司 2024-03-26 CN claimed
US-8044210-B2 Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof MARVEL LIFESCIENCES LIMITED (GB) 2011-10-25 US claimed
US-20110045065-A1 SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF MARVEL LIFE SCIENCES LTD. (GB) 2011-02-24 US claimed
EP-2265253-A2 ORAL DOSAGE FORM CONTAINING A PYRIDINOL DERIVATIVE Marvel Lifesciences Limited (GB) 2010-12-29 EP claimed
EP-2265252-A2 OPHTHALMIC PREPARATION CONTAINING A PYRIDINOL DERIVATE Marvel Lifesciences Limited (GB) 2010-12-29 EP claimed
EP-2252265-A2 INJECTABLE PREPARATIONS AND A PROCESS OF PREPARATION THEREOF Marvel Lifesciences Limited (GB) 2010-11-24 EP claimed
WO-2009116077-A2 INJECTABLE PREPARATIONS AND A PROCESS OF PREPARATION THEREOF M.J.BIOPHARM PVT. LTD. (IN) 2009-09-24 WO claimed
WO-2009116076-A2 STERILE OPTHALMIC PREPARATIONS AND A PROCESS FOR PREPARATION THEREOF M. J. BIOPHARM PVT.LTD. (IN) 2009-09-24 WO claimed
WO-2009116078-A2 ORAL DOSAGE FORMULATIONS AND PROCESS OF PREPARATION THEREOF M. J. BIOPHARM PVT. LTD. (IN) 2009-09-24 WO claimed
EP-1911746-B1 THE SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR PREPARING THEREOF MARVEL LIFESCIENCES LTD (GB) 2009-08-26 EP claimed
US-20090198068-A1 SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF MARVEL LIFESCIENCES LIMITED (GB) 2009-08-06 US claimed
EP-1911746-A1 THE SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR PREPARING THEREOF Marvel Lifesciences Limited (GB) 2008-04-16 EP claimed
EP-1608326-A2 EFFICIENT OXIDATIVE HAIR PREPARATION COMPRISING FIBER STRUCTURE STABILIZATION BY MEANS OF RADICAL INTERCEPTORS Henkel Kommanditgesellschaft auf Aktien (DE) 2005-12-28 EP claimed
WO-2004087086-A2 EFFICIENT OXIDATIVE HAIR PREPARATION COMPRISING FIBER STRUCTURE STABILIZATION BY MEANS OF RADICAL INTERCEPTORS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2004-10-14 WO claimed
US-4578439-A Styryl pyridine cyanates, styryl pyrazine cyanates and polymers thereof THE DOW CHEMICAL COMPANY (US) 1986-03-25 US claimed
WO-2025151724-A1 PYRIDINYLOXYPYRIDINES AS MODULATORS OF ATP -BINDING CASSETTE TRANSPORTERS AND THEIR USE IN TREATING MEDICAL CONDITIONS RECTIFY PHARMACEUTICALS, INC. (US) 2025-07-17 WO disclosed
US-20250228835-A1 PYRIDINYLOXYPYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS RECTIFY PHARMACEUTICALS, INC. 2025-07-17 US disclosed
US-4578439-A Styryl pyridine cyanates, styryl pyrazine cyanates and polymers thereof THE DOW CHEMICAL COMPANY (US) 1986-03-25 US disclosed
US-4540745-A Allyl styryl pyridines and pyrazines and polymers thereof THE DOW CHEMICAL COMPANY (US) 1985-09-10 US disclosed
US-4539377-A HEAT RESISTANCE THE DOW CHEMICAL COMPANY (US) 1985-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110045065-A1 SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF GPX4, PGC, GSR CA1 3648/4885CA2 3323/4885KDM4E 2635/4885
US-20090198068-A1 SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF GPX4, GPX1, HMOX1 CA1 968/4885CA2 1549/4885KDM4E 4214/4885
US-20250228835-A1 PYRIDINYLOXYPYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS P2RY6, P2RY4, PNPO CA1 4825/4885CA2 1969/4885KDM4E 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.